Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

88.70 -0.65 (-0.73%)
Streaming Delayed Price Updated: 3:51 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From DexCom, Inc.
Via Business Wire
Earnings Scheduled For February 13, 2025
 
Via Benzinga
DexCom (DXCM) To Report Earnings Tomorrow: Here Is What To Expect
Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings tomorrow after the bell. Here’s what investors should know. 
Via StockStory
Is NASDAQ:DXCM on the Verge of a Major Breakout as a Strong Growth Stock?
Based on a technical and fundamental analysis of NASDAQ:DXCM we can say: DEXCOM INC (NASDAQ:DXCM)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
Should You Buy DexCom Stock Before Feb. 13?
Via The Motley Fool
Prediction: This Top Growth Stock Will Outperform the Market in the Next Decade
Via The Motley Fool
Deep Dive Into DexCom Stock: Analyst Perspectives (5 Ratings)
 
Via Benzinga
Expert Outlook: DexCom Through The Eyes Of 11 Analysts
 
Via Benzinga
Is NASDAQ:DXCM on the Verge of a Major Breakout as a Strong Growth Stock?
Exploring the Growth Potential of DEXCOM INC (NASDAQ:DXCM) as It Nears a Breakout. 
Via Chartmill
Got $2,000? 2 Top Growth Stocks to Buy and Hold for Years
Via The Motley Fool
For those who appreciate growth without the sticker shock, NASDAQ:DXCM is worth considering.
NASDAQ:DXCM is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
Dexcom Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call for February 13, 2025 at 4:30 p.m. Eastern Time.
From DexCom, Inc.
Via Business Wire
Lululemon To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
NASDAQ:DXCM qualifies as a high growth stock and is consolidating.
DEXCOM INC (NASDAQ:DXCM) qualifies as a high growth stock and is consolidating. 
Via Chartmill
1 Reason to Sell DexCom Stock, and 1 Reason to Buy
Via The Motley Fool
Peering Into DexCom's Recent Short Interest
 
Via Benzinga
This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
 
Via Benzinga
2 Healthcare Stocks to Buy Hand Over Fist in January
Via The Motley Fool
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook
From DexCom, Inc.
Via Business Wire
Health Tracking Is Moving To Smart Rings From Watches. Oura Leads Market.
Smart rings are one of the hottest consumer electronics categories, as evidenced by exhibitors at CES 2025. Oura leads the market. 
Via Investor's Business Daily
3 Beaten-Down Stocks That May Be Due for Big Comebacks in 2025
Via The Motley Fool
Key Takeaways From DexCom Analyst Ratings
 
Via Benzinga
3 Reasons to Buy DexCom Stock Like There's No Tomorrow
Via The Motley Fool
Exploring the Growth Potential of NASDAQ:DXCM as It Nears a Breakout.
Exploring the Growth Potential of DEXCOM INC (NASDAQ:DXCM) as It Nears a Breakout. 
Via Chartmill
Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference
From DexCom, Inc.
Via Business Wire
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
Via The Motley Fool
DEXCOM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of DexCom, Inc. - DXCM
From Kahn Swick & Foti, LLC
Via Business Wire
Dexcom Launches the First Generative AI Platform in Glucose Biosensing
From DexCom, Inc.
Via Business Wire
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
2 Excellent Healthcare Stocks to Hold Through the Next Decade
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.